Giant Cell Tumor of Bone
Information
- Disease name
- Giant Cell Tumor of Bone
- Disease ID
- Description
Disease area statistics
Chromosome band
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04255576 | Active, not recruiting | Phase 1/Phase 2 | Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone | October 10, 2019 | October 2023 |
| NCT03449108 | Active, not recruiting | Phase 2 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | April 27, 2018 | June 30, 2025 |
| NCT00680992 | Completed | Phase 2 | Study of Denosumab in Subjects With Giant Cell Tumor of Bone | September 9, 2008 | May 17, 2018 |
| NCT00396279 | Completed | Phase 2 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | July 10, 2006 | February 1, 2011 |
| NCT02996734 | Completed | Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment | April 2016 | December 2016 | |
| NCT05402865 | Completed | A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone | November 10, 2021 | February 18, 2022 | |
| NCT03301857 | Completed | Phase 4 | Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 | November 13, 2017 | July 27, 2023 |
| NCT04002817 | Completed | Giant Cell Tumor of the Bone in Young Patients | June 5, 2019 | June 30, 2020 | |
| NCT00464620 | Completed | Phase 2 | Trial of Dasatinib in Advanced Sarcomas | May 2007 | May 2017 |
| NCT05813665 | Not yet recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone | April 2023 | September 2028 |
| NCT03295981 | Recruiting | Phase 3 | Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | May 3, 2018 | January 2026 |
| NCT04586660 | Recruiting | Phase 4 | Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone | August 17, 2023 | October 16, 2027 |
| NCT05595603 | Recruiting | Phase 2 | Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage | March 2023 | December 1, 2026 |
| NCT00889590 | Terminated | Phase 2 | Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) | December 2008 | July 2015 |
| NCT03358212 | Unknown status | Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China | March 1, 2018 | June 1, 2021 | |
| NCT03259152 | Unknown status | Phase 3 | Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone | May 1, 2016 | May 1, 2019 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0011847
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018212